Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 60
Healthy volunteers: yes

Brief summary:
According to the ICH Guidance Document E14, all non-antiarrhythmic drugs should be evaluated for their ability to prolong the QT interval which represents the duration of ventricular depolarization and subsequent repolarization. The primary objective of the study is to assess the effect of anagrelide on QT/QTc interval following a therapeutic and supratherapeutic dose of anagrelide when compared to placebo and a positive control.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: Anagrelide 0.5 mg intervention 2: Anagrelide 2.5 mg intervention 3: Moxifloxacin intervention 4: Placebo
Intervention descriptions: intervention 1: 0.5mg Anagrelide single oral dose intervention 2: 2.5mg Anagrelide single oral dose intervention 3: 400 mg Moxifloxacin single oral dose intervention 4: Anagrelide placebo + Moxifloxacin placebo single oral dose

Protocol document: